Eli Lilly Wins Back CVS Health, Reverting Novo Advantage
Eli Lilly said it reached an agreement with CVS Health to extend coverage of its approved GLP-1 drugs through CVS Caremark. The change reverses CVS’s prior 2025 decision making Novo Nordisk’s GLP-1 preferred and excluding Lilly’s Zepbound; CVS spokesperson said clients will have equal access and consumers will face the same co-pays. Caremark coverage starts June 1 for Foundayo and Oct. 1 for Zepbound.
Coverage parity with Novo should support demand visibility for Lilly’s GLP-1 franchise and reduce competitive share risk from PBM formulary decisions.
CVS agreed to extend coverage of Lilly’s top GLP-1s, restoring access after previously favoring Novo and excluding Zepbound.
Near-term upside bias as coverage timing (June 1 for Foundayo; Oct. 1 for Zepbound) de-risks utilization assumptions; magnitude depends on how much the market had priced the prior exclusion.
Background
CVS previously made Novo Nordisk the preferred GLP-1 provider in 2025, excluding Lilly’s Zepbound and contributing to a ~12% drop in LLY shares; this agreement reverses that stance.
Why it matters
By restoring coverage parity, CVS reduces a major channel risk for Lilly and improves near-to-mid-term visibility into GLP-1 prescription demand through Caremark.
Market relevance
This is a channel-access catalyst: CVS’s PBM coverage reversal directly affects patient access and competitive dynamics in US GLP-1 obesity medications.
Market effects
PBM formulary reversals can quickly change GLP-1 utilization and competitive share expectations across the sector.
Primarily US demand/channel impact via CVS Caremark PBM coverage decisions.
Moderate; US PBM access can influence global sentiment toward GLP-1 leaders but does not directly change ex-US regulatory timelines.
Alternative perspectives
Equal access may not translate to equal uptake if patient/plan behavior or pricing/rebate structures still favor one product.
The article omits rebate economics, formulary tier placement details, and whether CVS’s decision affects net pricing/margins—key drivers for both LLY demand and CVS PBM profitability.
Key entities
- companyEli Lilly and Company
GLP-1 manufacturer whose coverage was restored by CVS for Foundayo and Zepbound.
- companyCVS Health
PBM operator (Caremark) that agreed to extend coverage for Lilly’s GLP-1s and equalize access vs Novo.
- companyNovo Nordisk
Competitor whose preferred-provider advantage with CVS is being rolled back to equal access.
